AstraZeneca rises on entering into distribution services agreement with Sun Pharma
Astrazeneca Pharma India is currently trading at Rs. 9161.15, up by 29.15 points or 0.32% from its previous closing of Rs. 9132.00 on the BSE.
The scrip opened at Rs. 9449.00 and has touched a high and low of Rs. 9449.00 and Rs. 9130.00 respectively. So far 651 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 10653.05 on 13-Jun-2025 and a 52 week low of Rs. 6222.35 on 21-Nov-2024.
Last one week high and low of the scrip stood at Rs. 9449.00 and Rs. 9100.40 respectively. The current market cap of the company is Rs. 22935.00 crore.
The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 7.99% and 17.01% respectively.
AstraZeneca Pharma India (AstraZeneca) has entered into distribution services agreement with Sun Pharmaceutical Industries (Sun Pharma) for the distribution of Sodium Zirconium Cyclosilicate (SZC) powder for oral suspension 5 g in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India.
Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma whereas Sun Pharma will promote and distribute the therapy as Gimliand. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorization along with the import license of the molecule.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.
